MetaCap

Oramed Pharmaceuticals Inc. (ORMP)

NASDAQ: ORMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.57-0.12 (-3.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ORMP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$155.24M
Dividend yield
7.00% ($0.00)
Ex-dividend date
Jan 16, 2026
52-week range
2.52 – 5.47
Day range
3.54 – 3.71
Volume / Avg
285.67K / 173.38K
Beta
—

52-week range

$2.52$5.47

ORMP stock today

Shares of Oramed Pharmaceuticals (ORMP) finished lower on Nov 20 at $3.57, a drop of 3.25% or $0.12 per share, versus the S&P 500's 3.70% decline. At this level, ORMP sits in the middle of its 52-week range of $2.52 to $5.47: 34.7% below the high, set on Aug 27, 2026 and 41.7% above the low. ORMP is up 25.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.4%.

Oramed Pharmaceuticals trades at 1.0x its trailing twelve-month earnings per share of $3.41.

Summary generated from market data by MetaCap's automated system. Methodology

About Oramed Pharmaceuticals

Company profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Nadav Kidron Esq.
Headquarters
New York, NY
Website
oramed.com

Financial highlights

Full financials

In fiscal 2025, Oramed Pharmaceuticals generated $2.0 million in revenue. Net income was $64.0 million, for a net margin of 3202.5% versus a median of -637.6% in the prior 5 years. Gross margin was 0.7% and operating margin -754.4%.

Oramed Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.00M—$1.34M$2.70M$2.70M
Growth——-50.43%0.00%-0.26%
Net income$64.05M$-19.06M$5.09M$-36.56M$-22.99M
EPS (diluted)$1.50$-0.48$0.14$-0.94$0.78

Analyst forecast

Forecast

Consensus

none

Avg. price target

$7.00+96.08%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.43 vs $0.43

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.25
Ex-dividend date
Jan 16, 2026

ORMP news

All ORMP news

Oramed Pharmaceuticals peers

Health Care sector
ORMP peer companies
CompanyPrice% ChgMarket capCompare
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs ORMP
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs ORMP
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs ORMP
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs ORMP
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs ORMP
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs ORMP
BBOTBridgeBio Oncology Therapeutics Inc.1.81-2.69%$145.25Mvs ORMP
ABEOAbeona Therapeutics Inc.2.42-1.22%$165.31Mvs ORMP

Indexes, lists and sector

Oramed Pharmaceuticals stock FAQ

What is Oramed Pharmaceuticals's stock price today?

ORMP last traded at $3.57 as of Nov 20, 4:00 PM EST, down 3.25% on the day. Prices are delayed at least 15 minutes.

Does Oramed Pharmaceuticals pay a dividend?

Yes. Oramed Pharmaceuticals pays $0.00 per share annually, a 7.00% yield. The most recent dividend of $0.25 had an ex-dividend date of Jan 16, 2026.

What is ORMP's P/E ratio?

ORMP trades at a trailing P/E ratio of 1.05.

Who is Oramed Pharmaceuticals's CEO?

Mr. Nadav Kidron Esq. is the chief executive officer of Oramed Pharmaceuticals Inc..

Has ORMP ever split its stock?

Yes. The most recent ORMP stock split was a 1-for-12 split on Jan 23, 2013.

What is the ORMP 52-week high?

The 52-week high for ORMP is $5.47 and the 52-week low is $2.52. The stock is currently 34.7% below its high.

Compare ORMP